Dong-A ST, ST Pharm, and ST GenBio to Operate Joint Booth
Showcasing Technological Capabilities and Global Market Entry Strategies
Dong-A Socio Group announced on June 13 that Dong-A ST, ST Pharm, and ST GenBio will participate in the 2025 Bio International Convention (BIO USA), which will be held in Boston, United States, from June 16 to 19 (local time).
Bio USA is the world's largest pharmaceutical and biotechnology exhibition, organized by the Biotechnology Innovation Organization (BIO) in the United States. Every year, more than 20,000 professionals from the pharmaceutical and biotechnology industries from over 70 countries around the world attend the event. Participants introduce their R&D achievements and pipelines, engage in various business meetings to attract investment, pursue technology exports and imports, and strengthen global partnerships.
At this exhibition, Dong-A ST, ST Pharm, and ST GenBio will operate a joint booth, focusing on promoting each company's unique technological capabilities and global market entry strategies. Park Jaehong, President and Head of R&D at Dong-A ST, Sung Mujae, President of ST Pharm, and Choi Kyeongeun, President of ST GenBio, will be present at the booth to conduct business meetings and promotional activities in person.
Dong-A ST will introduce 14 clinical-stage pipelines in oncology, immunology and inflammatory diseases, neurological diseases, and endocrine diseases, as well as 24 early and preclinical-stage pipelines. The company will also showcase research achievements and development strategies in new modalities such as exosome-based drug delivery systems, mRNA-LNP (messenger RNA-lipid nanoparticle) platform technology, and AAV (adeno-associated virus)-mediated gene therapy. Its subsidiary, Aptys, will also travel to Boston for business meetings. Aptys plans to present the technological differentiation and scalability of its ADC linker platform 'AbClick®', as well as the current status of 'AT-211 (DA-3501)', a Claudin18.2-targeted therapy for gastric and pancreatic cancers.
ST Pharm will highlight its high-quality synthesis technology and precision analytics for 'sgRNA (Single Guide RNA)', a key component of the RNA gene-editing system 'CRISPR/Cas', as well as its enzyme-based hybrid approach. The company will also introduce STP0404, the first Allosteric HIV-1 Integrase Inhibitor (ALLINI) candidate for treating HIV (human immunodeficiency virus) through a novel mechanism, and STP1002, which is being developed as a treatment for advanced solid tumors including colorectal cancer.
ST GenBio will promote its active pharmaceutical ingredients (APIs) and prefilled syringe (PFS) CMO services, which are based on its successful FDA (U.S. Food and Drug Administration) cGMP (current Good Manufacturing Practice) inspection and EMA (European Medicines Agency) GMP certification. The company emphasizes its quality systems and production capabilities that have been validated by global regulatory agencies.
To accelerate its global market expansion, ST GenBio is planning to increase its annual production capacity to 28 million PFS (prefilled syringes) by expanding its 'harvest line' to improve cell culture line utilization and enhance multi-product manufacturing flexibility, as well as by introducing new aseptic filling facilities. In addition, to meet growing global demand, the company is strategically considering expanding its production infrastructure, including the potential construction of a second plant with a capacity of 35kL. At this exhibition, ST GenBio aims to expand collaboration opportunities with global clients based on its global quality reliability and production capacity expansion strategy.
A Dong-A Socio Group representative stated, "Through Bio USA, we will showcase the differentiated technological capabilities and competitiveness of Dong-A ST, ST Pharm, and ST GenBio to the world," adding, "We will strive to achieve tangible business results such as technology exports, investment attraction, and the expansion of global partnerships."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
